Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant nivolumab vs ipilimumab in melanoma
Melanoma · PERIO-MEL-01 · v2
This claim makes two promises at once: that adjuvant nivolumab beats adjuvant ipilimumab both at keeping melanoma from coming back (relapse-free survival) and at keeping patients alive longer (overall survival). On the first promise the evidence is strong and consistent: in the one large head-to-head trial, nivolumab reduced recurrences at every follow-up point [3][16][7]. On the second promise the same trial does not deliver: when the survival data matured, the difference in deaths was not statistically significant and the result could not rule out no benefit [16], and later survival rates were reported side by side with no significance test [7]. Because the claim joins the two promises with 'and', it can only be as true as its weaker half, and the overall-survival half is not demonstrated here. That is why the panel judged the claim as worded to fall short despite the compelling recurrence data.
The recurrence-free survival advantage of nivolumab over ipilimumab is demonstrated repeatedly in CheckMate 238: hazard ratio 0.65 at the primary readout [3], 0.71 at four years (51.7% vs 41.2%, p=0.0003) [16], and 0.72 at five years (50% vs 39%) [7], with consistency across stage, PD-L1 and BRAF subgroups and at 24 months (HR 0.66, P<0.0001) [8]. The overall-survival picture is different: the mature analysis reports OS HR 0.87 (95% CI 0.66-1.14, p=0.31) with four-year OS 77.9% vs 76.6% [16], and five-year OS of 76% vs 72% at 75% data maturity (228 of 302 planned events) reported without a significance test [7]. A mixture-cure model estimates a numerically higher cure rate with nivolumab (48.3% vs 38.2%) [23], but this is a modelled, partly indirect estimate rather than a measured survival difference. Almost all of this evidence originates from the single CheckMate 238 trial [3][16][7][8][11][13]. The contested point: The division is entirely about the overall-survival limb: the recurrence data are not in dispute, but the one mature OS analysis shows a hazard ratio whose confidence interval crosses 1 and a non-significant p value [16]. Whether this reflects a genuine absence of survival benefit or merely immature, underpowered data (fewer deaths than anticipated) cannot be resolved from the corpus [16][7].
All 33 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim asserts an overall-survival improvement, but the single mature OS analysis [16] reports HR 0.87 (95% CI 0.66-1.14, p=0.31) — a non-significant result whose confidence interval crosses 1. The OS limb of the compound claim is not supported and is arguably refuted on current data.
RFS is a surrogate endpoint; the claim conjoins it with the hard endpoint (OS) that the trial did not meet. Treating RFS superiority as if it carried OS is an indirectness overreach.
Where it remains uncertain. The single mature overall-survival analysis is non-significant (HR 0.87, 95% CI 0.66-1.14, p=0.31 [16]; 5-year OS 76% vs 72% with no significance test [7]), so the claim's OS half is unsupported.
Aleatory
OS was analysed with 211 of 302 anticipated deaths (~73% of the power needed for significance) [16] and at 75% maturity [7], so chance and event accrual leave the OS estimate unstable.
The load-bearing papers from a corpus of 33, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT establishes the RFS superiority of nivolumab over ipilimumab (HR 0.65).
“Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab.”
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab vs ipilimumab in resected stage IIIB/C or IV melanoma, RFS at 18-month minimum follow-up.Key limitations: OS not reported at this follow-up · RFS only
5-year OS numerically higher but reported without significance test and immature; does not establish OS benefit.
“RFS with nivolumab remained superior to ipilimumab (HR = 0.72; 95% confidence interval, 0.60-0.86; 5-year rates of 50% vs. 39%).”
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab vs ipilimumab in resected stage IIIB-C/IV melanoma at 62-month minimum follow-up.Key limitations: OS not significant / immature · descriptive OS comparison
Confirms durable RFS benefit at 4 years.
“4-year overall survival was 77·9% (95% CI 73·7-81·5) with nivolumab and 76·6% (72·2-80·3) with ipilimumab (HR 0·87 [95% CI 0·66-1·14]; p=0·31).”
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab vs ipilimumab RFS and initial OS in resected stage IIIB-C/IV melanoma.Key limitations: OS not significant (HR 0.87, p=0.31) · fewer deaths than planned, OS underpowered
RFS remained significantly longer with nivolumab (HR 0.66, P<0.0001) across subgroups; overall survival is not reported here.
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab vs ipilimumab RFS/DMFS at 24-month minimum follow-up.Key limitations: conference abstract · OS not reported
4 of 33 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The RFS component is Established but the OS component is explicitly non-significant, and a compound claim cannot score above its falsified limb.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Mature overall-survival analysis. The claim's OS limb rests on an immature, non-significant estimate [16][7]; only final-event OS data can confirm or refute an OS advantage. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Report CheckMate 238 overall survival at the pre-planned full event count (302 deaths) with a formal hazard ratio and significance test.
Open question: Does adjuvant nivolumab confer a statistically significant overall-survival benefit over ipilimumab in resected stage IIIB-IV melanoma? Why it is still open: The only mature OS estimate in the corpus is non-significant (HR 0.87, 95% CI 0.66-1.14, p=0.31) at ~73% of planned deaths [16], with 5-year rates reported without a significance test [7].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19